BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 15522063)

  • 1. Rituximab as treatment for minimal residual disease in hairy cell leukaemia.
    Cervetti G; Galimberti S; Andreazzoli F; Fazzi R; Cecconi N; Caracciolo F; Petrini M
    Eur J Haematol; 2004 Dec; 73(6):412-7. PubMed ID: 15522063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cladribine in hairy cell leukemia.
    Belani R; Saven A
    Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
    Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
    Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
    Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia.
    Lauria F; Lenoci M; Annino L; Raspadori D; Marotta G; Bocchia M; Forconi F; Gentili S; La Manda M; Marconcini S; Tozzi M; Baldini L; Zinzani PL; Foà R
    Haematologica; 2001 Oct; 86(10):1046-50. PubMed ID: 11602410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Complete remission after Rituximab treatment in refractory hairy cell leukemia].
    Petruskevicius I; Bukh A; Mertz H; Johnsen HE
    Ugeskr Laeger; 2008 Jun; 170(26-32):2350. PubMed ID: 18570771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Monitoring minimal residual disease in patients with hairy cell leukemia in complete remission after treatment with 2-chlorodioxyadenosine].
    Zák P; Chrobák L; Dĕdic K; Podzimek K
    Vnitr Lek; 2000 Oct; 46(10):697-703. PubMed ID: 11344629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hairy cell leukemia--a potentially curable malignancy. Selected aspects of purine analog therapy].
    Rucińska M; Machaczka M; Załuska A; Skotnicki AB
    Przegl Lek; 1998; 55(7-8):400-6. PubMed ID: 10021885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission.
    Filleul B; Delannoy A; Ferrant A; Zenebergh A; Van Daele S; Bosly A; Doyen C; Mineur P; Glorieux P; Driesschaert P
    Leukemia; 1994 Jul; 8(7):1153-6. PubMed ID: 7913513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which role for rituximab in hairy cell leukemia? Reflections on six cases.
    Malfuson JV; Fagot T; Konopacki J; Souleau B; Cremades S; de Revel T
    Acta Haematol; 2010; 123(2):110-6. PubMed ID: 20051682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with hairy cell leukemia with 2-chloro-2'-deoxyadenosine (2-CdA).
    Robak T; Krykowski E; Błasińska-Morawiec M; Urbańska-Ryś H
    Arch Immunol Ther Exp (Warsz); 1994; 42(1):25-9. PubMed ID: 7503629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
    Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis.
    Else M; Dearden CE; Matutes E; Garcia-Talavera J; Rohatiner AZ; Johnson SA; O'Connor NT; Haynes A; Osuji N; Forconi F; Lauria F; Catovsky D
    Br J Haematol; 2009 Jun; 145(6):733-40. PubMed ID: 19344416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic myeloid leukaemia and hairy cell leukaemia coexisting in a single patient: difficulties at diagnosis and rational of the therapeutic strategy.
    Orciuolo E; Fazzi R; Galimberti S; Testi C; Azzara' A; Carulli G; Petrini M
    Leuk Res; 2006 Mar; 30(3):349-53. PubMed ID: 16182365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia.
    Del Poeta G; Del Principe MI; Buccisano F; Maurillo L; Capelli G; Luciano F; Perrotti AP; Degan M; Venditti A; de Fabritiis P; Gattei V; Amadori S
    Cancer; 2008 Jan; 112(1):119-28. PubMed ID: 17999417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
    Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
    Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful ambulatory treatment of patients with hairy-cell leukemia using one cycle of the purine analog cladribine. 'Hemato-oncologic volwassen Nederland' (HOVON) Study Group].
    Raemaekers JM; van 't Veer MB; Bogman MJ
    Ned Tijdschr Geneeskd; 1996 Aug; 140(31):1600-4. PubMed ID: 8768814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment of patients with hairy cell leukemia (HCL) using a single cycle of 2-chloro-2'-deoxyadenosine (CdA).
    Jehn U; Gawaz M; Grunewald R; Hill W; Lorenz B; Stôtzer O
    Anticancer Res; 1993; 13(5C):1809-14. PubMed ID: 7903521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.